by Andreas Kremer | Jun 16, 2023
Luxembourg, June 14th 2023. Today a consortium of public and private entities announced the official launch of IDERHA (Integration of heterogenous Data and Evidence towards Regulatory & HTA Acceptance). The consortium aims to propel health care innovation in...
by Andreas Kremer | Jun 1, 2022
EU-PEARL is a strategic partnership between the public and private sectors to shape the future of clinical trials. This innovative and challenging enterprise aims to create a framework for patient-centric integrated research platform (IRP) trials, through which novel...
by Andreas Kremer | Nov 15, 2021
OPTIMA aims to harness the power of artificial intelligence, to advance treatments and facilitate decision-making for physicians and patients with prostate, breast and lung cancer. At the heart of OPTIMA will be Europe’s first interoperable, large scale oncology data...
by Lisa Blum | Oct 6, 2021
Myeloid immune cells are important mediators in the pathology of many diseases, especially in diseases associated with chronic inflammation (DACI). Recent advancements in molecular profiling technologies have led to the generation of large data sets, many of those not...
by Lisa Blum | Feb 3, 2021
Immune cells that are empowered by gene-engineering to seek and destroy cancer cells (engineered T cell therapy) constitute a transformative novel treatment that has the potential to cure cancer. Multiple new versions of this therapy are being developed for distinct...